{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-054826","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.857492+00:00","generated_at":"2026-06-07T21:02:16.693022+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Roivant: IMVT-1402 600 mg Phase 1 data shows best-in-class potential; 74% IgG reduction","bullets":["Four weekly SC doses of 600 mg IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% reduction.","Serum albumin and LDL-C at Day 29 showed no significant change from baseline (p>0.05), indicating placebo-like safety.","Steady-state IgG reduction expected to reach ~80% with continued weekly dosing, matching batoclimab's timing of 6-8 weeks.","Treatment was well tolerated with only mild or moderate adverse events observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-054826","json":"https://secwatch.observer/filing/0001140361-23-054826.json","markdown":"https://secwatch.observer/filing/0001140361-23-054826.md","text":"https://secwatch.observer/filing/0001140361-23-054826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123054826/0001140361-23-054826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123054826/ef20015486_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:02:16.693022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}